In a paper published in Proceedings of the National Academy of Sciences, researchers from Technion and Tel Aviv University ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

A California gene-therapy pioneer has filed for bankruptcy. Eli Lilly and Astellas have already lined up bids to buy pieces ...

Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...

Sangamo Therapeutics will lay off 51 members of its workforce while retaining 77 people to continue work on the programs central to Astellas and Eli Lilly’s bids. In conjunction with plans to file for ...

Alamo Biologics LLC filed for Chapter 11 last week after two California companies took steps to collect on a nearly $3.5 million agreed judgment. The San Antonio company said it doesn't have the money ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Half a year after being spurned by the FDA and following deep layoffs, IO Biotech has decided to close its doors for good. The Danish biotech has ceased operations and said goodbye to its employees, C ...

Large language models trained on vast datasets could speed genomics research, streamline clinical documentation, improve real-time diagnostics, support clinical decision-making, accelerate drug ...

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...